StockNews.com Upgrades Haemonetics (NYSE:HAE) to Strong-Buy

Haemonetics (NYSE:HAE – Get Rating) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Friday.

Other research analysts also recently issued research reports about the stock. Morgan Stanley lifted their price objective on shares of Haemonetics from $84.00 to $88.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 8th. Barrington Research lifted their price objective on shares of Haemonetics from $103.00 to $111.00 in a research report on Friday. Citigroup cut their price objective on shares of Haemonetics from $95.00 to $90.00 in a research report on Monday, April 3rd. Mizuho boosted their target price on shares of Haemonetics from $110.00 to $115.00 and gave the stock a “buy” rating in a research report on Wednesday, February 8th. Finally, JMP Securities boosted their target price on shares of Haemonetics from $105.00 to $115.00 in a research report on Friday. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average price target of $103.17.

Haemonetics Trading Up 4.2 %

Shares of HAE opened at $89.45 on Friday. Haemonetics has a 1-year low of $52.84 and a 1-year high of $91.39. The company has a 50-day moving average of $81.40 and a 200 day moving average of $81.70. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 2.50 and a beta of 0.44. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.11 and a quick ratio of 1.99.

Hedge Funds Weigh In On Haemonetics

Large investors have recently made changes to their positions in the company. Wipfli Financial Advisors LLC acquired a new position in Haemonetics during the third quarter worth $25,000. Byrne Asset Management LLC grew its holdings in shares of Haemonetics by 64.0% during the first quarter. Byrne Asset Management LLC now owns 305 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 119 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Haemonetics by 65.2% during the fourth quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 135 shares in the last quarter. State of Wyoming purchased a new stake in shares of Haemonetics in the fourth quarter valued at about $28,000. Finally, Romano Brothers AND Company purchased a new stake in shares of Haemonetics in the fourth quarter valued at about $31,000.

Haemonetics Company Profile

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.